Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Indivior ( (INDV) ) has issued an announcement.
Indivior reported strong first-quarter 2026 results on April 30, 2026, with total net revenue rising 19% year-on-year to $317 million and SUBLOCADE net revenue up 32% to $232 million, driven by 20% U.S. volume growth and record new patient starts. The company delivered record adjusted EBITDA of $164 million, sharply reduced operating expenses, and GAAP net income nearly doubled to $89 million, underscoring improved profitability.
On the back of this performance, Indivior raised its full-year 2026 guidance, lifting total net revenue expectations to $1.215 billion–$1.285 billion and SUBLOCADE revenue to $950 million–$990 million, while projecting significantly higher adjusted EBITDA. The group also strengthened its balance sheet with a $500 million convertible notes issue used largely to repay term debt, executed $125 million of share repurchases under a $400 million program, and reoriented its pipeline by handing back INDV-6001 development to Alar and halting internal development of INDV-2000 after a Phase 2 miss, while seeking external opportunities for the asset.
The most recent analyst rating on (INDV) stock is a Buy with a $54.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
Spark’s Take on INDV Stock
According to Spark, TipRanks’ AI Analyst, INDV is a Neutral.
The score is held back primarily by weaker financial quality (negative equity and inconsistent/negative cash flow despite improved profitability) and bearish technicals. Offsetting these, the latest earnings call guidance points to strong 2026 EBITDA and operating cash flow improvement, while valuation appears mid-range with no dividend support.
To see Spark’s full report on INDV stock, click here.
More about Indivior
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on treatments for opioid use disorder, where it is a leader in long-acting injectable therapies. Its primary product is SUBLOCADE, a monthly injectable buprenorphine formulation, with a core market focus on the U.S. addiction treatment landscape and related healthcare settings.
Average Trading Volume: 2,368,335
Technical Sentiment Signal: Buy
Current Market Cap: $4.16B
For a thorough assessment of INDV stock, go to TipRanks’ Stock Analysis page.